Detect and measure your integration sites with confidence
As the dominant viral delivery vector for approved cell therapies, lentivirus requires integration site analysis (ISA) to assess the risk of off-target insertional mutagenesis. Measuring these genomic insertions with the right analytically validated assay and a robust bioinformatics workflow is essential for patient safety in pre-clinical and clinical trials. Here we compare ISA data from industry standard methods to help you find the best path forward for your lentiviral-based therapy.
What you’ll learn:
- Performance characteristics of several NGS-based methods for integration site analysis
- Critical bioinformatic steps to generate meaningful data
- Experimental results characterized by false positive integration sites, on-target rate, and unique molecular identifier (UMI) diversity
Complete the form to download the tech note!